Clinical trial
Multiepitope Peptide Vaccination in Melanoma
NCT00153569 · Charite University, Berlin, Germany, Other · Unknown status
Key facts
| NCT number | NCT00153569 |
|---|---|
| Title | Multiepitope Peptide Vaccination in Melanoma |
| Official title | Phase II Study of Multiepitope Peptide Vaccination in Combination With Adjuvants GM-CSF and KLH in Metastatic Melanoma |
| Lead sponsor | Charite University, Berlin, Germany, Other |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Melanoma |
| Intervention type | Biological |
| Interventions | Tyrosinase, MAGE-3, GnTV |
| Enrollment | 25 |
| Start date | Mar 1, 2003 |
| Completion | Sep 1, 2005 |
| First posted | Sep 12, 2005 |
| Last update posted | May 26, 2010 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: